437 related articles for article (PubMed ID: 18840785)
1. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
[TBL] [Abstract][Full Text] [Related]
2. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
[TBL] [Abstract][Full Text] [Related]
4. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
5. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
6. Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels.
Johnson KM; Edgerton DS; Rodewald T; Scott M; Farmer B; Neal D; Cherrington AD
Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1085-91. PubMed ID: 17684104
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff.
Koyama A; Komori K; Otsuka R; Kajikuri J; Itoh T
J Vasc Surg; 2016 May; 63(5):1360-70. PubMed ID: 25656593
[TBL] [Abstract][Full Text] [Related]
8. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
Akarte AS; Srinivasan BP; Gandhi S
J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
[TBL] [Abstract][Full Text] [Related]
10. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
Ahrén B; Foley JE
Int J Clin Pract Suppl; 2008 Mar; (159):8-14. PubMed ID: 18269436
[TBL] [Abstract][Full Text] [Related]
11. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
[TBL] [Abstract][Full Text] [Related]
12. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
Burkey BF; Li X; Bolognese L; Balkan B; Mone M; Russell M; Hughes TE; Wang PR
J Pharmacol Exp Ther; 2005 Nov; 315(2):688-95. PubMed ID: 16027230
[TBL] [Abstract][Full Text] [Related]
13. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
Ahrén B; Winzell MS; Wierup N; Sundler F; Burkey B; Hughes TE
Regul Pept; 2007 Oct; 143(1-3):97-103. PubMed ID: 17482289
[TBL] [Abstract][Full Text] [Related]
14. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
Akarte AS; Srinivasan BP; Gandhi S
Eur J Pharm Sci; 2012 Apr; 45(5):546-51. PubMed ID: 22155545
[TBL] [Abstract][Full Text] [Related]
15. The scientific evidence: vildagliptin and the benefits of islet enhancement.
Mathieu C
Diabetes Obes Metab; 2009 May; 11 Suppl 2():9-17. PubMed ID: 19385979
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
17. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.
Nishizawa M; Moore MC; Shiota M; Gustavson SM; Snead WL; Neal DW; Cherrington AD
Am J Physiol Endocrinol Metab; 2003 May; 284(5):E1027-36. PubMed ID: 12569088
[TBL] [Abstract][Full Text] [Related]
18. Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization.
Johnson KM; Edgerton DS; Rodewald T; Scott M; Farmer B; Neal D; Cherrington AD
Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E380-4. PubMed ID: 18056788
[TBL] [Abstract][Full Text] [Related]
19. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
El-Ouaghlidi A; Rehring E; Holst JJ; Schweizer A; Foley J; Holmes D; Nauck MA
J Clin Endocrinol Metab; 2007 Nov; 92(11):4165-71. PubMed ID: 17698900
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.
Vedtofte L; Bodvarsdottir TB; Gotfredsen CF; Karlsen AE; Knudsen LB; Heller RS
Regul Pept; 2010 Feb; 160(1-3):106-14. PubMed ID: 20005262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]